Faculty

Carina Dolan, PharmD, MS Pharm, BCOP
Sr Director for Clinical Oncology and Pharmaceutical Outcomes
Pharmacy Solutions, Center for Pharmacy Practice Excellence
Vizient

Megan Mullalley, PharmD, BCOP, BCPS
System Oncology Pharmacy Manager
Intermountain Healthcare

Scott Freeswick, MS, PharmD
Vice President/Chief Pharmacy Officer
Memorial Sloan Kettering Cancer Center

Sylvia Bartel, RPH, MHP
Vice President
Dana Farber Cancer Institute

Julie Kennerly-Shah, PharmD, MS, MHA, BCPS
Associate Director, James Cancer Hospital Clinical Services
The Ohio State University – The James Cancer Hospital
 

Planning committee

Travis Hunerdosse, PharmD, MBA
Senior Director, Pharmacy Networks
Vizient 

Pei Jen Lin, PharmD, MS, BCPS
Lead Project Manager, Pharmacy Networks
Vizient
 

Disclosure of Financial Relationships:

Relevant Financial Relationships 

Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.

Scott Freeswick, MS, PharmD, speaker for this educational activity, is an advisor for Fresenius Kabi and Exelixis.

All relevant financial relationships listed for these individual(s) have been mitigated.

All others in a position to control content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Statement of Content Validity

Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.

FDA off-label/unapproved usage

Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.

Usage Disclosure: “Off-label/unapproved drug uses or products are mentioned within this activity.”

Evidence-based Content: “Low/absence of evidence-based topics are mentioned within this activity”

Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.